Gland Pharma Limited has successfully filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, prepared by RVR & Associates, confirms the company’s adherence to all relevant corporate governance standards and procedural requirements. This transparent disclosure underscores Gland Pharma’s ongoing commitment to regulatory excellence and operational integrity, ensuring that all policies and board procedures remain in full alignment with the necessary guidelines for the 2025-26 fiscal year.
Commitment to Corporate Governance
Gland Pharma Limited has reinforced its dedication to maintaining high standards of transparency and corporate governance. In accordance with mandated reporting requirements, the company has completed its comprehensive secretarial audit for the period concluding on March 31, 2026. This audit serves as a vital validation of the company’s internal controls and compliance mechanisms.
Review Findings and Compliance Status
The review conducted by RVR & Associates involved an exhaustive examination of the company’s internal documents, website disclosures, and filings submitted throughout the fiscal year. The findings confirm that Gland Pharma remained fully compliant across all key parameters, including:
- Policies and Procedures: All corporate policies are duly adopted and kept current with the latest regulatory updates.
- Website Transparency: The company maintains a functional and informative website with timely document dissemination.
- Performance Evaluation: Proper evaluation of the board, independent directors, and committees was conducted throughout the year.
- Related Party Transactions: All transactions were reviewed and approved by the audit committee as required.
Operational Integrity
The secretarial audit confirmed that no punitive actions were initiated against the company, its promoters, or its directors during the 2025-26 review period. Furthermore, the company has maintained full compliance regarding the preservation of records and the timely disclosure of material events, demonstrating a robust administrative framework. This clean report highlights the efficiency of Gland Pharma’s management in navigating complex regulatory environments while prioritizing shareholder interests.
Source: BSE
